CD20 Protein, Human, Recombinant (His & Avi)

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.

规格	价格/CNY		数量
100 μg	￥ 2,960	5日内发货
500 μg	￥ 11,800	5日内发货
1 mg	￥ 19,700	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 2,960

5日内发货

500 μg

￥ 11,800

5日内发货

1 mg

￥ 19,700

5日内发货

生物活性

Immobilized Human CD20, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.33μg/ml determined by ELISA.

产品描述

种属	Human
表达系统	E. coli
标签	C-His-Avi
蛋白编号	P11836-1
别名	MS4A2, Ly-44, LEU-16, MS4A1, Bp35, CD20 receptor, CVID5, MS4A-1, B1, S7, CD20S7, CD20
蛋白构建	Ile141-Ser188
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	16.8 kDa (predicted) same as Tris-Bis PAGE result.

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in 20 mM PB, 10% Glycerol, 0.4M Urea, 1 mM GSH, 0.1 mM GSSG (pH 7.0).
存储	It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.